Results 61 to 70 of about 1,437,121 (388)
Mathematical models for immunology:current state of the art and future research directions [PDF]
, 2016 The advances in genetics and biochemistry that have taken place over the last 10 years led to significant advances in experimental and clinical immunology.A Bauer, A Bellouquid, A Bellouquid, A Carbo, A Chakraborty, A Chakraborty, A Chavali, A Ghaffari, A Hamdache, A Malkin, A Mander, A Moskalensky, A Nag, A Perelson, A Pigozzo, A Prasad, A Smith, A Smith, A Tóth, B Chen, B Cumming, B Goldstein, B Hancioglu, B Kholodenko, B Kidd, B Rivière, B Rouse, B Su, B Thorne, B Zolnik, C Beauchemin, C Bianca, C Bianca, C Bianca, C Bianca, C Davis, C Dool van den, C Gerlach, C Macnamara, C Pommerenke, C Sinclair, D Bandura, D Barua, D Chen, D Choo, D Coombs, D Finlay, D Kirschner, D Laydon, D Liu, D Mallet, D Mathis, D Smith, D Winter, D Wylie, Doreen A. Cantrell, E Ahrens, E Castillo-Montiel, E Hawkins, E Mochan, E Newell, E Numfor, E Pearce, E Pearce, E Rykiel, E Stirk, F Castiglione, F Castiglione, F Crauste, F Fellizi, F Gross, F Pappalardo, F Pappalardo, G An, G Bogle, G Bogle, G Bonizzi, G Huynh, G Lythe, H Caswell, H Knútsdóttir, H Lee, H Miao, H Miao, H Zheng, I Bains, I Baltcheva, I Nahum-Shani, ID Braber, J Beltman, J Currie, J Day, J Dunster, J Faeder, J Flegg, J Flegg, J Gillard, J Heffernan, J Kim, J Köbig, J Linderman, J Mansfield, J Mattes, J Perley, J Reynolds, J Sekar, J Tan, J Wares, Joseph J. Gillard, K Blyuss, K Fujarewicz, K Ganeshan, K García-Martínez, K Janes, K Murphy, K Norris, K Popper, K Saeki, K Smith, K Yoshida, KH Farh, L Balagopalan, L Bayón, L Borghesi, L Canini, L Canini, L DePillis, L Pillis de, L Romani, M Artyomov, M Chaplain, M Fallahi-Sichani, M Figge, M Halling-Brown, M Itik, M Kalos, M Kolev, M Kolev, M Krummel, M Lever, M Mentis, M Nishikori, M Onsum, M Pogson, M Reed, M Sneddon, N Bellomo, N Bellomo, N Burroughs, N Burroughs, N Burroughs, N Cilfone, N Clifone, N Figueroa-Morales, N Kim, N Kronik, N Oreskes, N Strbo, O Dushek, O Serichantalergs, P Ankomah, P Cao, P Francois, P Gannon, P Johnson, P Kim, P Kim, P Kourilsky, P Morel, P Thagard, P Verdijk, Q Yang, R Andersen, R Antia, R Callard, R Callard, R Cheong, R Cheong, R Eftimie, R Eftimie, R Garnier, R Germain, R Germain, R Leander, R Maizels, R Malka, R Medzhitov, R Saenz, R Spreafico, R Stengel, R Williams, R Zinkernagel, Raluca Eftimie, RD Boer, S Adra, S Andrew, S Basak, S Celli, S Dai, S Gadhamsetty, S Gordon, S Henrickson, S Hoops, S Hugues, S Krishna, S Lawley, S Marino, S Marino, S Meraviglia, S Nagaraja, S Otto, S Prokopiou, S Qi, S Tay, S Villar, S Webb, T Lipniacki, T Sun, T Sun, T Tian, TH Lee, U Foryś, U Ledzewicz, U Schnell, V Ganusov, V Kocabas, W Shou, W Singer, Y Chew, Y Kim, Y Kim, Y Louzoun, Y Vodovotz, Y Vodovotz, Y Wang, YF Qi, Z Feng, Z Feng, Z Kabala, Z Shi, Z Yilmaz +240 morecore +3 more sourcesPatient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity
Molecular Oncology, EarlyView.This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert +16 morewiley +1 more sourceT-cell recognition is shaped by epitope sequence conservation in the host proteome and microbiome [PDF]
, 2016 Several mechanisms exist to avoid or suppress inflammatory T-cell immune responses that could prove harmful to the host due to targeting self-antigens or commensal microbes.Bancroft, Tara, Bresciani, Anne Gøther, Dillon, Myles B., Greenbaum, Jason, Nielsen, Morten, Paul, Sinu, Peters, Bjoern, Schommer, Nina, Sette, Alessandro +8 morecore +2 more sourcesReduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity
Molecular Oncology, EarlyView.A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh +8 morewiley +1 more sourceCyclic AMP pathway activation and extracellular zinc induce rapid intracellular zinc mobilization in Candida albicans [PDF]
, 2018 LK was supported by Innovation Fund Denmark, DK (4019-00019B). Pcovery ApS received funding from Wellcome Trust, Research Councils, UK (100480/Z/12), Novo Seeds, DK and Boehringer Ingelheim Venture Fund, D.Anja T. Fuglsang, Anne-Marie L. Winther, Duncan Wilson, Lasse Kjellerup, Lasse Kjellerup +4 morecore +3 more sourcesImproving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann +15 morewiley +1 more sourceClass IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio +13 morewiley +1 more source
